Today Phase Holographic Imaging (PHI) launches a new website. The new website has been created to comprehensively provide extensive product information, as well as an introduction to the range of cell biology applications supported by the HoloMonitor® system.
University of California, San Francisco and Phase Holographic Imaging establish Center of Excellence
University of California, San Francisco (UCSF) and Phase Holographic Imaging (PHI) have agreed to expand their on-going collaboration and establish a regional Holographic Imaging Cytometry Center of Excellence, located at the UCSF Helen Diller Family Comprehensive Cancer Center.
Using HoloMonitor®, researchers at Harvard Medical School and Boston Children’s Hospital have developed a novel non-invasive method for distinguishing between active and dormant cancer cells.
HoloMonitor® Wound Healing Assay: The assay meets the unmet market demand of both quantifying cell movement automatically and in great detail. Wound healing assays are one of the most used laboratory methods to study cell movement. Conventional wound healing assays are either manual or just measure the collective movement of a cell population.
A first HoloMonitor was recently deployed at QIMR Berghofer Medical Research Institute in Brisbane Australia. With the purchase, the institute upgrades its quantitative time-lapse cytometry capacity to also include instrumentation for measuring the behavior of individual cells in a cell population, without requiring the cells to be labeled with toxic chemicals or through genetic manipulation.
GlycoImaging is a collaboration project between PHI, Malmö University and four international research institutions. By combining PHI’s HoloMonitor technology with a new type of cancer probes, more sensitive methods to detect and diagnose cancer at an earlier stage than what is possible today.
Using HoloMonitor® technology from PHI the scientists have been able to follow and measure important dynamics of cancer cells in ways not possible with conventional methods, which has led to the novel research results.
Japan’s foremost medical research institute, The Institute of Medical Science at University of Tokyo, recently purchased two HoloMonitor M4. Together with RIKEN and Kyoto University, the institute spearheads Japan’s national effort to become the undisputed leader of regenerative medicine in the world.
EU grants 2.1 million euro to Phase Holographic Imaging and Malmö University with partners for joint cancer research
The European Commission has appointed Phase Holographic Imaging,Bundesanstalt für Material-forschung und Prüfung (Germany’s federal technology research institute), Malmö, Umeå, Copenhagen and Turku University to develop improved methods for clinically diagnosing cancer.
In the October issue of Molecular Cancer Therapeutics the American Association of Cancer Research (AACR) highlights the novel nanomedicine against ovarian cancer developed by scientists from the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University.